Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Isabella Henderson, Nisali A Gunawardane, Ruben I Kuzniecky

Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1 Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and sudden unexpected death in epilepsy (SUDEP).2 Early identification of DRE is critical to enable timely exploration […]

John Bodensteiner, AAN 2018 – Expert perspective on Duchenne muscular dystrophy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 2nd 2018

John Bodensteiner (Consultant, Child and Adolescent Neurology), our Paediatric Neurology Section Editor for US Neurology, shares his expert perspective on Duchenne muscular dystrophy.

Questions

1. What do you consider the most promising current and emerging treatment options for Duchenne Muscular Dystrophy (DMD)? (0:11)
2. Could you tell us a little about the CINRG Duchenne Natural History Study? (0:34)
3. What were the findings of the CINRG study on the long-term effects of glucocorticoids in patients with DMD? (1:52)
4. On the basis of current evidence, what do you consider to be the optimal treatment regimen for children with DMD? (3:09)

Speaker disclosure: John Bodensteiner has nothing to disclose in relation to this video interview.

 

Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup